BioStock: High potential with Iconovo’s new inhalation platform ICOpre

Iconovo has recently made the strategic decision to invest heavily in developing a new inhalation platform – ICOpre. With this investment, the company hopes to be able to offer generic versions of GSK’s Ellipta portfolio, which is expected to have a market value of 5 BUSD by 2024. BioStock takes a closer look at the stakes involved for Iconovo in making this big bet.

Read the full article at biostock.se:

https://www.biostock.se/en/high-potential-with-iconovos-new-inhalation-platform-icopre/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

Subscribe

Quick facts

BioStock: High potential with Iconovo’s new inhalation platform ICOpre
Tweet this